A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck



Status:Completed
Conditions:Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, Cancer, Cancer, Gastrointestinal
Therapuetic Areas:Gastroenterology, Oncology
Healthy:No
Age Range:18 - Any
Updated:12/6/2017
Start Date:April 2011
End Date:December 2012

Use our guide to learn which trials are right for you!

A Phase 2 Indication Identification Study of LY2523355 in Patients With Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

The purpose of the study is to estimate the rate of response for patients with ovarian,
non-small cell lung, prostate, colorectal, gastroesophageal, and head and neck cancers who
are administered LY2523355.


Inclusion Criteria:

- Diagnosis of ovarian, non-small cell lung, prostate, colorectal, gastroesophageal
cancer (adenocarcinoma of the esophageal cancer, stomach, or gastroesophageal
junction), or squamous cell cancer of the head and neck

- Have measurable disease defined by Response Evaluation Criteria in Solid Tumors
(RECIST) 1.1 guidelines (except prostate cancer participants)

- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

- Are willing to follow study procedures for the duration of the study

- Are willing to use an approved contraceptive method during treatment and for 3 months
after discontinuation of study treatment

Exclusion Criteria:

- Have a serious preexisting medical condition that would preclude participation in the
study

- Are pregnant or lactating

- Have received treatment within 28 days of first dose of LY2523355 with a drug that has
not received regulatory approval for any indication

- Have symptomatic, untreated, or uncontrolled central nervous system (CNS) metastases

- Have a second active primary malignancy or a history of a second malignancy requiring
cytotoxic therapy

- Have QTc interval greater than 470 millisecond (msec) or intraventricular conduction
delay (IVCD) with QRS greater than 120 msec on screening electrocardiogram (ECG)

- Have active symptomatic fungal, bacterial, and/or known viral infection including
active human immunodeficiency virus (HIV) or viral (A, B, C) hepatitis

- Participants with pneumonia, evidence of obstructive pneumonitis, other respiratory
infections, or infection from other sources are to be excluded
We found this trial at
18
sites
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
?
mi
from
Billings, MT
Click here to add this to my saved trials
Charleston, South Carolina 29412
?
mi
from
Charleston, SC
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
?
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
?
mi
from
Germantown, TN
Click here to add this to my saved trials
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
?
mi
from
Jonesboro, AR
Click here to add this to my saved trials
?
mi
from
Macon, GA
Click here to add this to my saved trials
?
mi
from
Marietta, GA
Click here to add this to my saved trials
?
mi
from
Memphis, TN
Click here to add this to my saved trials
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
?
mi
from
Post Falls, ID
Click here to add this to my saved trials
?
mi
from
Valdosta, GA
Click here to add this to my saved trials
?
mi
from
Westwood, KS
Click here to add this to my saved trials
?
mi
from
Wichita, KS
Click here to add this to my saved trials